The REgistry of Very Early Estrogen and AnovuLation

NCT06583408 — Recruiting, 100000 participants, Mayo Clinic

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT06583408, acronym REVEAL
StatusRecruiting
Study typeObservational
Enrollment100000 (Estimated)
SponsorMayo Clinic (Other)
ConditionsHypothalamic Amenorrhea, Functional, Hypothalamic Amenorrhea, Functional Hypogonadotropic Hypogonadism
InterventionsAutomated Self-Administered 24-hour Dietary Assessment Tool (ASA24), REVEAL Questionnaire (Other)
Datesstart 2024-07-01, primary completion 2029-08-01 (estimated), completion 2029-08-01 (estimated), first posted 2024-09-04, last updated 2025-11-21
Locations2 sites in United States

Related Papers Related Patents Related Grants Related Experts
All trials for Hypothalamic Amenorrhea, Functional All trials for Hypothalamic Amenorrhea All trials of Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24) All trials of REVEAL Questionnaire

-Summary

The purpose of this study is to to build a registry of women with early estrogen loss due to Functional Hypothalamic Amenorrhea (FHA) to understand the prevalence, racial and ethnic diversity of this condition.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
Women with > 3 months amenorrheaOther: Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24); Other: REVEAL QuestionnaireWomen aged 18-40 years old with a diagnosis of functional hypothalamic amenorrhea, or lab results that are within the inclusion criteria.
  • Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24) (Other): Subjects will complete the ASA food diary for 2 weekdays and 1 weekend day
  • REVEAL Questionnaire (Other): Subjects will complete the REVEAL questionnaire form. This form includes questions about current and past medical history, including reproductive history, lifestyle specifics, and assessment of current health status.

+Outcome measures

Primary outcomes

  • Study Participants [5 years]: Establish and maintain a comprehensive registry of patients diagnosed with Functional Hypothalamic Amenorrhea (FHA). This registry will include detailed demographic information, clinical data, and longitudinal follow-up to track the prevalence, underlying causes, risk factors, and prognosis of FHA. It will also facilitate the collection of data on racial and ethnic disparities, lifestyle factors, psychological stressors, hormonal imbalances, and the impact of various treatment interventions on long-term health outcomes collected through questionnaires done at baseline and yearly.

Secondary outcomes

  • Assessing the Impact of Amenorrhea on Women's Health: Symptoms, Care Experiences, and Work Productivity [5 years]: Improve understanding of women's overall experience of Functional Hypothalamic Amenorrhea (FHA) by documenting the types of care received, frequency and quality of healthcare interactions, and patient satisfaction with the care provided. This includes detailed assessments of specific treatments or therapies received, the involvement of multidisciplinary care approaches, and the extent of follow-up care. Additionally, to quantify the impact of FHA on lost work productivity, including the number of workdays missed, impact on work performance, and economic burden associated with amenorrhea-related issues, measured at baseline and then yearly using questionnaires.
  • Impact of Social, Early Life, and Pregnancy Factors on Functional Hypothalamic Amenorrhea [5 years]: Enhance the understanding of how social determinants of health-such as socioeconomic status, education, access to healthcare, and community environment-contribute to the development of Functional Hypothalamic Amenorrhea (FHA). Additionally, the study will explore the impact of childhood adversity, including exposure to trauma, abuse, neglect, or chronic stress, on the likelihood of developing FHA. The relationship between pregnancy complications, such as preterm birth, miscarriage, or gestational conditions, and the onset of FHA will also be analyzed. Data will be collected through baseline and annual questionnaires throughout the study, providing a comprehensive understanding of these factors' roles in the development of FHA.

+Eligibility

Sex: Female, ages: 18 Years to 40 Years

Inclusion Criteria:

* 3 or more months of consecutive amenorrhea with a diagnosis of functional hypothalamic amenorrhea or screening hormones consistent with functional hypothalamic amenorrhea including but not limited to:

  * Estradiol: < 50pg/mL
  * LH: < 10 IU/mL
  * FSH: < 10 IU
  * Testosterone: 2 - 45 ng/dL
  * Free Testosterone: 0.1 - 6.4 pg/mL
  * FT4: 0.93 - 1.70 ng/dL
  * Prolactin: < 20 ng/mL
  * AMH: > 1 ng/mL
  * Urine or serum human chorionic gonadotropin: Negative
* LH:FSH Ratio <1
* No signs of male-like hair growth on the upper lip, chin, chest, abdomen, buttocks, or back
* Does not have a diagnosis for secondary amenorrhea, including prolactinoma, PCOS, premature ovarian insufficiency, pituitary surgery, infection, or infarction
* Premenopausal status determined by WISE criteria
* Able to give informed consent
* Able to read English

Exclusion Criteria:

* Parturition/lactating in the last 6-12 months
* Lack of consent

+Locations (2)

FacilityCityCountryStatus
Mayo ClinicJacksonville, FloridaUnited StatesRecruiting
Mayo ClinicRochester, MinnesotaUnited StatesRecruiting

+Investigators